OpenAI acquires Orchestra Bio, AI entities take over drug development

OpenAI announced the acquisition of San Francisco startup Orchestra Bio, which has developed AI agents to help pharmaceutical companies track the progress of drug development projects. Orchestra's team and platform will be integrated into OpenAI's life sciences product line Rosalind, aimed at biologists and chemists, with the transaction amount undisclosed. Orchestra was founded in the fall of 2022, with seed funding from Andreessen Horowitz, Definition Capital, Insight Partners, and 8VC, raising a total of approximately $20 million.

According to OpenAI, a new drug can take up to 15 years from initial conception to approval in the United States, and the cost of bringing a single approved drug to market can exceed $2.6 billion, with less than 10% of candidate drugs entering human trials ultimately reaching the market. Orchestra's AI agents can automatically monitor tasks and flag issues, analyze how setbacks like production batch failures affect the overall development project, compile relevant information, and compare response strategies, ultimately allowing scientists and project leaders to make decisions.

This acquisition follows competitor Anthropic's acquisition of Coefficient Bio for approximately $400 million in April, reflecting the competition among AI labs for new drug development workflows. In April, OpenAI launched the model GPT-Rosalind specifically designed for biology and drug discovery, available only to vetted U.S. corporate clients such as Amgen and Moderna, with the accompanying product Rosalind Workbench connecting the model to research tools and data.